Auspex Pharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY14 | FY13 | |
|---|---|---|
| Revenue | — | — |
| Operating income | −$6.1M | −$2.6M |
| Net income | −$10.1M | −$2.3M |
| Total assets | $151.1M | $38.9M |
| Total liabilities | $26.3M | $22.0M |
| Equity | $121.1M | −$64.9M |
| EPS (diluted) | — | — |
| Shares out. | 27.1M | 173,147 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2014- Operating margin
- —
- Net margin
- —
- Return on equity
- −8.4%
- Return on assets
- −6.7%
- Return on capital (ROCE)
- −4.4%
- Liabilities / assets
- 17.4%
- Debt / equity
- 0.22×
- Book value / share
- $4.46
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2014- Altman Z″ (distress)
- 7.92safe
- Accruals / assets
- 21.7%high accruals
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 warning● 2 good- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Flynn James E10% owner | May 5, 2015 | U | 490,069 | — |
| Thomas, Mcnerney &Amp; Partners Ii, LlcDirector | May 5, 2015 | U | 4.8M | — |
| Greer R ScottDirector | May 5, 2015 | U | 7,190 | — |
| Sarshar SepehrDirector | May 5, 2015 | U | 242,574 | — |
| Ferguson Rodney ADirector | May 5, 2015 | U | 2.5M | — |
| Proehl Gerald TDirector | May 5, 2015 | U | 1,466 | — |
| Saks Samuel ROfficer — Chief Development Officer | May 5, 2015 | U | 67,338 | — |
| Chowrira Bharat MOfficer — Chief Operating Officer | May 5, 2015 | U | 8,297 | — |
| Stamler David AOfficer — Chief Medical Officer | May 5, 2015 | U | 1,627 | — |
| Schmid John P.Officer — Chief Financial Officer | May 5, 2015 | U | 144,444 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMay 5, 2015
- Regulation FD disclosureApr 17, 2015
- Entered a material agreement · Director / officer changeMar 30, 2015
- Results of operationsMar 16, 2015
- Director / officer changeFeb 20, 2015
- Regulation FD disclosure · Other material eventJan 12, 2015
- Regulation FD disclosure · Other material eventDec 16, 2014
- Results of operationsNov 10, 2014
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13D/AAUSPEX PHARMACEUTICALS, INC. - AMEND. NO. 2May 28, 2015
- 15-12BMay 15, 2015
- SC 13G/AMay 14, 2015
- 4May 7, 2015
- 4PRIMARY DOCUMENTMay 7, 2015
- 4FORM 4 SUBMISSIONMay 6, 2015
- 4FORM 4 SUBMISSIONMay 6, 2015
- 4FORM 4 SUBMISSIONMay 6, 2015
- 4FORM 4 SUBMISSIONMay 6, 2015
- 4FORM 4 SUBMISSIONMay 6, 2015
- 4FORM 4 SUBMISSIONMay 6, 2015
- 4FORM 4 SUBMISSIONMay 6, 2015
- 4FORM 4 SUBMISSIONMay 6, 2015
- 4FORM 4 SUBMISSIONMay 6, 2015
- 4FORM 4 SUBMISSIONMay 6, 2015
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.